Aclarion Secures U.S. Patent for AI-Driven Chronic Back Pain Assessment Technology
Aclarion has obtained a U.S. patent for its AI-powered platform that analyzes spinal data to identify sources of chronic low back pain, potentially improving surgical outcomes and expanding access to more consistent diagnostics.
Aclarion, Inc., a commercial-stage healthcare technology company, announced the issuance of U.S. Patent #12,601,803, titled "System for Machine Learning-Based Model Training and Prediction for Evaluation of Pain." The patent covers the company's machine learning platform for analyzing magnetic resonance spectroscopy data to help physicians identify painful discs in the spine. This development strengthens Aclarion's intellectual property portfolio to 64 issued and pending patents worldwide and protects its use of artificial intelligence in future versions of its Nociscan platform.
The newly issued patent enables Aclarion to further automate biomarker identification, accelerate report generation, and reduce manual quality reviews through AI-based automated data quality controls. These controls detect and exclude low-quality acquisition signals, such as excessive lipids or spectral artifacts, which will enable consistent, reproducible outputs across different imaging systems and clinical sites. According to Brent Ness, Chief Executive Officer of Aclarion, "This patent strengthens the foundation of our platform by protecting how we leverage AI to transform complex spectroscopy data into meaningful, actionable information that physicians can integrate into everyday practice."
The technology addresses a significant global healthcare challenge, as chronic low back pain affects approximately 266 million people worldwide. Clinical data has demonstrated up to a 97% surgical success rate when all Nociscan-positive discs are treated alongside other diagnostic tools. The patent represents a key step toward broader clinical adoption by ensuring standardized classifications across different healthcare settings. For more information about the company's technology, visit https://www.aclarion.com.
The patent coverage extends to machine learning models that extract quantitative biomarkers from MRS spectral data to generate standardized pain-related classifications. This approach combines proprietary signal processing with machine learning to create a scalable and defensible method for evaluating pain that could redefine how spine conditions are assessed. The company's strategy focuses on building a differentiated, software-driven platform in the large and underserved chronic low back pain market. Additional company updates are available at https://tinyurl.com/aconnewsroom.
Aclarion's cloud-based Nociscan platform converts complex MRS spectral data into clinically actionable insights, helping physicians distinguish between painful and non-painful spinal discs. The platform's ability to provide critical insights into pain location gives physicians clarity to optimize treatment strategies. The patent protection enhances Aclarion's ability to scale its technology while maintaining strong gross margins through increased automation and efficiency in its diagnostic processes.